Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders

Abstract Background As choices of treatments for bipolar disorder types I (BD1) and II (BD2) and major depressive disorder (MDD) continue to evolve, we reviewed studies directly comparing current clinical usage rates of medicinal treatments for these disorders. Methods Comprehensive searching of fiv...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:International Journal of Bipolar Disorders
المؤلفون الرئيسيون: Carolina Hernandorena, Micaela Dines, Alessandro Miola, Nicolas A. Nuñez, Leonardo Tondo, Ross J. Baldessarini, Gustavo H. Vázquez
التنسيق: مقال
اللغة:الإنجليزية
منشور في: SpringerOpen 2025-07-01
الموضوعات:
الوصول للمادة أونلاين:https://doi.org/10.1186/s40345-025-00381-y
_version_ 1849417989544214528
author Carolina Hernandorena
Micaela Dines
Alessandro Miola
Nicolas A. Nuñez
Leonardo Tondo
Ross J. Baldessarini
Gustavo H. Vázquez
author_facet Carolina Hernandorena
Micaela Dines
Alessandro Miola
Nicolas A. Nuñez
Leonardo Tondo
Ross J. Baldessarini
Gustavo H. Vázquez
author_sort Carolina Hernandorena
collection DOAJ
container_title International Journal of Bipolar Disorders
description Abstract Background As choices of treatments for bipolar disorder types I (BD1) and II (BD2) and major depressive disorder (MDD) continue to evolve, we reviewed studies directly comparing current clinical usage rates of medicinal treatments for these disorders. Methods Comprehensive searching of five literature databases through March 2024 identified reports on clinical drug prescription rates for BD and MDD patients. Rates were summarized and compared by random-effects meta-analyses with R-Studio software. Results A total of 18 reports (2006–2023) supported comparisons of clinically prescribed treatments for 17,572 mood-disorder patients (mean age 42.8 years; 7936 BD1 age 43.2 years; 6309 BD2, age 43.3; 3327 MDD, age 40.0). Among diagnoses: (BD1 vs. BD2 vs. MDD), treatments differed as: lithium (54.4% vs. 38.0% vs. 6.78%), second-generation antipsychotics (41.6% vs. 22.3% vs. 15.9%), valproate (25.7% vs. 21.5%; no MDD data), lamotrigine (13.1% vs. 27.2%; no MDD data), and antidepressants (34.9% vs. 46.4% vs. 77.5%). International use of lithium for BD appeared to increase between 2006 and 2023. Limitations Outcomes were heterogeneous and requiring inclusion of lithium may introduce selection bias. Conclusions Clinical treatment selections for BD1, BD2, and MDD patients differed substantially. Use of modern antipsychotics is undergoing major increases for both BD and MDD; optimal use of antidepressants for BD remains uncertain; and notably, international use of lithium tended to increase in the present data.
format Article
id doaj-art-07a4cf5bbbc44d1e9ece9d85cb05ed74
institution Directory of Open Access Journals
issn 2194-7511
language English
publishDate 2025-07-01
publisher SpringerOpen
record_format Article
spelling doaj-art-07a4cf5bbbc44d1e9ece9d85cb05ed742025-08-20T03:45:43ZengSpringerOpenInternational Journal of Bipolar Disorders2194-75112025-07-0113111210.1186/s40345-025-00381-yClinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disordersCarolina Hernandorena0Micaela Dines1Alessandro Miola2Nicolas A. Nuñez3Leonardo Tondo4Ross J. Baldessarini5Gustavo H. Vázquez6Centre for Neuroscience Studies, Queen’s UniversityHospital General de Agudos Dr. Juan A. FernándezDepartment of Neuroscience, University of PadovaDepartment of Psychiatry, University of UtahInternational Consortium for Mood & Psychotic Disorder Research, McLean HospitalInternational Consortium for Mood & Psychotic Disorder Research, McLean HospitalCentre for Neuroscience Studies, Queen’s UniversityAbstract Background As choices of treatments for bipolar disorder types I (BD1) and II (BD2) and major depressive disorder (MDD) continue to evolve, we reviewed studies directly comparing current clinical usage rates of medicinal treatments for these disorders. Methods Comprehensive searching of five literature databases through March 2024 identified reports on clinical drug prescription rates for BD and MDD patients. Rates were summarized and compared by random-effects meta-analyses with R-Studio software. Results A total of 18 reports (2006–2023) supported comparisons of clinically prescribed treatments for 17,572 mood-disorder patients (mean age 42.8 years; 7936 BD1 age 43.2 years; 6309 BD2, age 43.3; 3327 MDD, age 40.0). Among diagnoses: (BD1 vs. BD2 vs. MDD), treatments differed as: lithium (54.4% vs. 38.0% vs. 6.78%), second-generation antipsychotics (41.6% vs. 22.3% vs. 15.9%), valproate (25.7% vs. 21.5%; no MDD data), lamotrigine (13.1% vs. 27.2%; no MDD data), and antidepressants (34.9% vs. 46.4% vs. 77.5%). International use of lithium for BD appeared to increase between 2006 and 2023. Limitations Outcomes were heterogeneous and requiring inclusion of lithium may introduce selection bias. Conclusions Clinical treatment selections for BD1, BD2, and MDD patients differed substantially. Use of modern antipsychotics is undergoing major increases for both BD and MDD; optimal use of antidepressants for BD remains uncertain; and notably, international use of lithium tended to increase in the present data.https://doi.org/10.1186/s40345-025-00381-yAnticonvulsantsAntidepressantsAntipsychoticsBipolar disorder types I and IIClinical prescription patternsLithium
spellingShingle Carolina Hernandorena
Micaela Dines
Alessandro Miola
Nicolas A. Nuñez
Leonardo Tondo
Ross J. Baldessarini
Gustavo H. Vázquez
Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders
Anticonvulsants
Antidepressants
Antipsychotics
Bipolar disorder types I and II
Clinical prescription patterns
Lithium
title Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders
title_full Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders
title_fullStr Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders
title_full_unstemmed Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders
title_short Clinical prescription of lithium, anticonvulsants antipsychotics, and antidepressants for major mood disorders
title_sort clinical prescription of lithium anticonvulsants antipsychotics and antidepressants for major mood disorders
topic Anticonvulsants
Antidepressants
Antipsychotics
Bipolar disorder types I and II
Clinical prescription patterns
Lithium
url https://doi.org/10.1186/s40345-025-00381-y
work_keys_str_mv AT carolinahernandorena clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders
AT micaeladines clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders
AT alessandromiola clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders
AT nicolasanunez clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders
AT leonardotondo clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders
AT rossjbaldessarini clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders
AT gustavohvazquez clinicalprescriptionoflithiumanticonvulsantsantipsychoticsandantidepressantsformajormooddisorders